At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
Radical hysterectomy via laparotomy (open surgery) is the standard surgical approach for people with early-stage cervical cancer. A radical hysterectomy involves removal of the uterus, cervix, parametria (tissue beside the cervix), and upper part of the vagina; the ovaries, fallopian tubes, and nearby lymph nodes may also be removed. With laparotomy, the operation is performed through a large incision in the abdomen.
-
Glioblastomas that have an "unmethylated" MGMT gene are less likely to respond to the standard chemotherapy drug temozolomide. In this study, researchers are comparing three investigational treatments (abemaciclib, CC-115, and neratinib) with the standard treatment (temozolomide and radiation therapy) in patients newly diagnosed with glioblastoma.
-
Researchers want to find the best dose of [AC-225]RTX-2358 to use safely in people with advanced sarcoma. The people in this study have sarcoma that has come back or keeps growing after treatment.
-
The purpose of this study is to establish a registry of patients with a rare disease called pediatric-onset opsoclonus myoclonus ataxia syndrome (POOMAS). POOMAS affects the brain, spinal cord, and other nerves. Its exact cause is unknown, though a small number of patients with neuroblastoma may have this condition.
-
Prostate cancers initially need the male hormone testosterone for growth. Hormone therapies that lower the level of testosterone are among the best treatments for prostate cancers that have metastasized (spread). The benefits of hormone treatments often do not last, however. Over time, many prostate cancers keep growing even with hormonal therapies. These are called castration-resistant prostate cancers (CRPC).
-
People with endometrial cancer often gain weight during and after chemotherapy. Medicines to reduce the risk of an allergic reaction for people receiving chemotherapy can also raise blood sugar. Weight gain can affect overall health and cancer recovery.
- A Phase 1 Study of D3L-001 in People With Advanced Breast Cancer
Full Title A Phase 1, Open-label Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3L-001 Monotherapy in Subjects with HER2-Positive Advanced Solid Tumors
Purpose
Researchers want to find the best dose of D3L-001 to treat advanced breast cancer. The people in this study have breast cancer that cannot be cured with standard therapies. Their tumors also make the HER2 protein, which plays a role in cancer growth.
D3L-001 is a drug that binds to two proteins. One protein is found on the surface of cancer cells, and the other is on immune cells called T cells. D3L-001 may strengthen your immune system’s ability to fight cancer cells by helping your own cells to destroy your tumor. It is given intravenously (by vein).
Who Can Join
To join this study, there are a few conditions. You must:
- Have metastatic or locally advanced breast cancer that keeps growing after treatment or cannot be treated using standard therapies.
- Have breast cancer that makes HER2.
- Have recovered from the serious side effects of prior therapies before getting D3L-001.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Shanu Modi’s office at 646-888-5243.
Protocol
24-240Phase
Phase I (phase 1)Disease Status
Relapsed or RefractoryInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT05957536ClinicalTrials.gov
-
Gemcitabine and oxaliplatin (GemOx) is a standard chemotherapy combination used to treat a cancer of the bile ducts called cholangiocarcinoma. In this study, researchers want to see if adding another treatment that is delivered by a pump device (hepatic arterial infusion or HAI) to GemOx therapy is more effective than GemOx alone for patients with previously untreated inoperable cholangiocarcinoma. The HAI pump, which is implanted in the abdomen during a surgical procedure, continuously delivers the drugs floxuridine and dexamethasone directly to the liver.
-
Researchers want to find the best dose of LY4050784 to treat advanced solid tumors. The people in this study have cancer that cannot be cured with standard therapies. Their tumors also have a mutation (change) in the SMARCA4 and/or BRG1 genes, which play a role in cancer growth.
-
Researchers in this study want to determine if combining the drug venetoclax with standard chemotherapy may be more effective than standard chemotherapy alone in children and adolescents with relapsed acute myeloid leukemia (AML). Venetoclax blocks Bcl-2, a protein that helps cancer cells to survive and resist the effects of cancer treatments. By blocking Bcl-2, venetoclax may kill cancer cells and/or make other treatments more effective.